D-1073-2019 Class I Terminated

Recalled by Pfizer Inc. — New York, NY

FDA drug recall D-1073-2019 was initiated by Pfizer Inc. on Mar 15, 2019 and is designated Class I. Reason for recall: Presence of Particulate Matter; glass particulates The recall status is terminated (terminated Jan 27, 2021). Affected quantity: 283,400 vials.

Recall details

Product Type
Drugs
Report Date
Apr 10, 2019
Initiation Date
Mar 15, 2019
Termination Date
Jan 27, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
283,400 vials

Product description

8.4% Sodium Bicarbonate Injection, USP 50 mEq (1 mEq/mL) 4.2 grams (84 mg/mL) 50 mL Single-dose fliptop vial, 25 vials per carton, Rx only Hospira, Inc. Lake Forest, IL 60045 USA ---- NDC 0409-6625-02

Reason for recall

Presence of Particulate Matter; glass particulates

Distribution pattern

United States and Puerto Rico

Code information

Lots: 79-238-EV Exp. 1 July 2019; 79-240-EV Exp. 1 July 2019; 80-088-EV Exp. 1 August 2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1073-2019
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-1073-2019. Report a data issue: hello@regdatalab.com.